Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders.

Drug metabolism and pharmacokinetics - 1 Oct 2024

Sakaguchi Kenta, Naito Takafumi, Hoshikawa Kohei, Miyadera Yukari, Tanaka Hironari, Nakatsugawa Emi, Furuta Takahisa, Sugimoto Ken, Kawakami Junichi

Abstract excerpt

Factors that determine clinical responses to vonoprazan remain unknown. This study aimed to characterize plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders. Fifty-three patients who were receiving vonoprazan for at least 3 days were enrolled. Blood samples for determination of plasma vonoprazan and its metabolite (ODA-VP) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to Biomarkers

Share to Cytochrome P-450 CYP3A

Share to Genetic Variation

Share to Pyrroles

Share to Sulfonamides

Source

Identifiers

PMID: 39428315
DOI: 10.1016/j.dmpk.2024.101027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders.PMID 39428315Read ↗

Drugs as CYP3A Probes, Inducers, and InhibitorsSemantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.Semantic proximity Read ↗

Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.Semantic proximity Read ↗

Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.Semantic proximity Read ↗

Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.Semantic proximity Read ↗

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.Semantic proximity Read ↗

CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.Semantic proximity Read ↗

Flavonoids As CYP3A4 Inhibitors In VitroSemantic proximity Read ↗

Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.Semantic proximity Read ↗

Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters.Semantic proximity Read ↗

Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.